Bufei Yishen Granule for Reducing Acute Exacerbation in GOLD Stage 3 or 4 COPD

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

Bufei Yishen Granule for Reducing Acute Exacerbation in GOLD Stage 3 or 4 COPD: A Randomized, Double-blind, Placebo Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03976713
• Other study ID #: TCM for GOLD stage 3 or 4 COPD
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: June 2019
• Est. completion date: December 2020

Study information

• Verified date: May 2019
• Source: Henan University of Traditional Chinese Medicine
• Contact: Xueqing Yu, Doctor
• Phone: 86-371-66248624
• Email: yxqshi[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to establish the treatment scheme of Bufei Yishen granule for GOLD stage 3 or 4 chronic obstructive pulmonary disease (COPD), reducing acute exacerbation, improving exercise capacity and forming high quality evidence.

Description:

COPD is a highly prevalent disease, with a prevalence among people 40 years of age or older of 10.1% worldwide and 13.7% in China. COPD has become the third leading cause of death worldwide. Frequent acute exacerbation and exercise limitation broadly exist in COPD patients, especially those in GOLD stage 3 or 4. Although appropriate pharmacological therapies have been proven to be effective in COPD management, however, many gaps are still to be filled. For example, the adverse effects of pharmacologic therapies can never be ignored. The investigator's previous studies suggested that traditional Chinese medicine (TCM) has effect on GOLD stage 3 or 4 COPD.

This is a multicenter, randomized, double-blind, placebo controlled trial to evaluate the effect of Bufei Yishen granule on reducing acute exacerbation in GOLD stage 3 or 4 COPD subjects. After a 14-day run-in period, 348 subjects will be randomly assigned to treatment group or control group for 52-week treatment. The primary outcomes are frequency and duration of acute exacerbation. The secondary outcomes include mortality, pulmonary function, clinical symptoms, exercise capacity, quality of life and treatment satisfaction. Safety will also be assessed.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 348
• Est. completion date: December 2020
• Est. primary completion date: June 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• A confirmed diagnosis of GOLD stage 3 or 4 COPD.

• Syndrome differentiation meets criteria of Qi deficiency of the lung and spleen syndrome, Qi deficiency of the lung and kidney syndrome or Qi and Yin deficiency of the lung and kidney syndrome.

• Age ranges from 40 years to 80 years.

• With informed consent signed.

Exclusion Criteria:

• Pregnant and lactating women.

• Patients with severe cardiovascular and cerebrovascular diseases.

• Patients with severe liver and kidney diseases.

• Patients with asthma, bronchiectasis, active pulmonary tuberculosis, pulmonary embolism, chronic respiratory failure or other severe respiratory diseases.

• Patients with tumor after resection, radiotherapy or chemotherapy in the past 5 years.

• Patients with severe neuromuscular disorders, severe arthritis or severe peripheral vascular diseases.

• Patients with severe cognitive and psychiatric disorders.

• Patients with diabetes.

• Patients who were administered oral glucocorticoids in the past 4 weeks.

• Patients who have participated in other clinical studies in the past 4 weeks.

• People who are allergic to the treatment drugs.

• Patients who have experienced one or more acute exacerbation in the past 4 weeks.

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• Bufei Yishen granule
Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks.
• Placebo Bufei Yishen granule
Placebo Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks. The placebo granule consists of dextrin, bitter and 5% of the Bufei Yishen granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group.
• Tiotropium Bromide Powder for Inhalation
Tiotropium Bromide Powder for Inhalation will be used once daily (18 µg each time) for 52 weeks.

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Henan University of Traditional Chinese Medicine	Zhengzhou	Henan

Sponsors (2)

Lead Sponsor	Collaborator
Henan University of Traditional Chinese Medicine	ShuGuang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of acute exacerbation	Frequency of acute exacerbation will be recorded.	Up to week 52.
Primary	Duration of acute exacerbation	Duration of acute exacerbation will be recorded.	Up to week 52.
Secondary	Mortality	The mortality will be calculated.	Up to week 52.
Secondary	FEV1	Forced expiratory volume in one second ( FEV1) will be used to assess pulmonary function.	Change from baseline FEV1 at week 26 and 52.
Secondary	Clinical symptom assessment questionnaire	Clinical symptom assessment questionnaire of COPD will be used to assess symptom.	Change from baseline clinical symptom assessment questionnaire scores at week 13, 26, 39 and 52.
Secondary	6MWD	Six-minute walk distance (6MWD) will be conducted to assess exercise capacity	Change from baseline 6MWD at week 13, 26, 39 and 52.
Secondary	CAT	COPD assessment test (CAT) will be used to assess quality of life.	Change from baseline CAT scores at week 13, 26, 39 and 52.
Secondary	SF-36	The MOS 36-Item Short-Form Health Survey (SF-36) will be used to assess quality of life.	Change from baseline SF-36 scores at week 13, 26, 39 and 52.
Secondary	mCOPD-PRO	The modified COPD patient-reported outcome scale (mCOPD-PRO) will be used to assess quality of life. The mCOPD-PRO contains 27 items in three domains. mCOPD-PRO scores range from 0 to 4 with a decrease in score showing higher health status.	Change from baseline mCOPD-PRO scores at week 13, 26, 39 and 52.
Secondary	mESQ-COPD	The modified effectiveness satisfaction questionnaire for COPD (mESQ-COPD) will be used to assess treatment satisfaction. The mESQ-COPD contains 19 items in four domains. mESQ-COPD scores range from 0 to 4 with a decrease in score showing higher treatment satisfaction.	Change from baseline mESQ-COPD scores at week 13, 26, 39 and 52.